Advice
following a full submission:
deferasirox (Exjade®) is accepted for restricted use within NHS Scotland for the treatment of chronic iron overload associated with the treatment of rare acquired or inherited anaemias requiring recurrent blood transfusions. It is not recommended for patients with myelodysplastic syndromes.
Patients with myelodysplastic syndromes, the commonest cause of transfusion-dependent anaemia, were poorly represented in the clinical trial population and the economic case was not demonstrated in this group.
Download detailed advice81KB (PDF)
Medicine details
- Medicine name:
- deferasirox (Exjade)
- SMC ID:
- 347/07
- Indication:
- Chronic iron overload associated with the treatment of rare acquired or inherited anaemias requiring recurrent blood transfusions
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 12 February 2007